Xenetic Biosciences, Inc. (XBIO)
Total Valuation
XBIO has a market cap or net worth of $6.13 million. The enterprise value is -$2.85 million.
Market Cap | 6.13M |
Enterprise Value | -2.85M |
Important Dates
The last earnings date was Thursday, March 21, 2024, after market close.
Earnings Date | Mar 21, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
XBIO has 1.54 million shares outstanding. The number of shares has increased by 7.44% in one year.
Shares Outstanding | 1.54M |
Shares Change (YoY) | +7.44% |
Shares Change (QoQ) | +0.40% |
Owned by Insiders (%) | 19.05% |
Owned by Institutions (%) | 1.10% |
Float | 1.25M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.41 |
Forward PS | n/a |
PB Ratio | 0.63 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.84, with zero debt.
Current Ratio | 11.84 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.40% and return on invested capital (ROIC) is -46.10%.
Return on Equity (ROE) | -36.40% |
Return on Assets (ROA) | -33.70% |
Return on Capital (ROIC) | -46.10% |
Revenue Per Employee | $634,997 |
Profits Per Employee | -$1.03M |
Employee Count | 4 |
Asset Turnover | 0.21 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.30% in the last 52 weeks. The beta is 2.62, so XBIO's price volatility has been higher than the market average.
Beta (1Y) | 2.62 |
52-Week Price Change | -14.30% |
50-Day Moving Average | 3.86 |
200-Day Moving Average | 3.80 |
Relative Strength Index (RSI) | 44.06 |
Average Volume (30 Days) | 5,386 |
Short Selling Information
The latest short interest is 2,209, so 0.14% of the outstanding shares have been sold short.
Short Interest | 2,209 |
Short Previous Month | 8,664 |
Short % of Shares Out | 0.14% |
Short % of Float | 0.18% |
Short Ratio (days to cover) | 2.37 |
Income Statement
In the last 12 months, XBIO had revenue of $2.54 million and -$4.13 million in losses. Loss per share was -$2.71.
Revenue | 2.54M |
Gross Profit | 2.54M |
Operating Income | -4.52M |
Pretax Income | -4.13M |
Net Income | -4.13M |
EBITDA | -4.13M |
EBIT | -4.13M |
Loss Per Share | -$2.71 |
Balance Sheet
The company has $8.98 million in cash and no debt, giving a net cash position of $8.98 million or $5.83 per share.
Cash & Cash Equivalents | 8.98M |
Total Debt | n/a |
Net Cash | 8.98M |
Net Cash Per Share | $5.83 |
Equity / Book Value | 9.80M |
Book Value Per Share | 6.36 |
Working Capital | 8.78M |
Cash Flow
Operating Cash Flow | -4.11M |
Capital Expenditures | n/a |
Free Cash Flow | -4.11M |
FCF Per Share | -$2.69 |
Margins
Gross margin is 100.00%, with operating and profit margins of -177.79% and -162.78%.
Gross Margin | 100.00% |
Operating Margin | -177.79% |
Pretax Margin | -162.78% |
Profit Margin | -162.78% |
EBITDA Margin | -162.78% |
EBIT Margin | -162.78% |
FCF Margin | -161.98% |
Dividends & Yields
XBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.44% |
Shareholder Yield | -7.44% |
Earnings Yield | -67.43% |
FCF Yield | -67.10% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | Hold |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.
Last Split Date | May 15, 2023 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
XBIO has an Altman Z-Score of -21.02 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -21.02 |
Piotroski F-Score | 2 |